REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

09 Apr 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Cancer-Associated Thrombosis (CAT) · Phase 3 · Enrollment 860 · Sponsor: Regeneron Pharmaceuticals

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Cardiology on 09 Apr 2026. The item focuses on REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT07410117

Open Original Source More Feed Items

Related by Condition/Drug

AHA NewsRelated by Specialty

La Universidad de Míchigan otorgó una subvención de la American Heart Association para la educación y el entrenamiento de RCP

Cardiology • 22 May 2026

AHA NewsRelated by Specialty

Una donación de $1 millón impulsará la investigación sobre los defectos cardíacos congénitos

Cardiology • 22 May 2026

JAHARelated by Specialty

Study Design and Conceptual Framework of an Observational Study of Food Insecurity and Life's Essential 8 in College Students: The FRESH Study

Cardiology • 29 Apr 2026

JAHARelated by Specialty

Coronary Embolism in Atrial Fibrillation: A Distinct High‐Risk Phenotype With Residual Thromboembolic Risk Despite Anticoagulation

Cardiology • 29 Apr 2026

Feed Metadata

Source

ClinicalTrials.gov